Drug choices in the treatment of atrial fibrillation

American Journal of Cardiology

Volumn 85, Issue 10 SUPPL. 1, 2000, Pages 12-19

  Reiffel, James A ^a,b  

^a Electrophysiology Service   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; DOFETILIDE; SOTALOL;

CARDIOVERSION; CONFERENCE PAPER; DRUG CHOICE; DRUG FORMULATION; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; ELECTRIC COUNTERSHOCK; HUMANS; PHENETHYLAMINES; SOTALOL; SULFONAMIDES;

EID: 0034066541     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00902-4     Document Type: Conference Paper

References (62)

1. Prystowsky E.N., Benson W. Jr, Fuster V., Hart R.G., Kay G.N., Myerburg R.J., Naccarelli G.V., Wyse D.G. Management of patients with atrial fibrillation a statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association . Circulation. 93:1996;1262-1277.
2. Blitzer M., Costeas C., Kassotis J., Reiffel J.A. Rhythm management in atrial fibrillation - with a primary emphasis on pharmacological therapy part 1 . PACE Pacing Clin Electrophysiol. 21:1998;590-602.
3. Naccarelli G.V., Dell'Orfano J.T., Wolbrette D.L., Patel H.M., Luck J.C. Cost-effective management of acute atrial fibrillation role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy . Am J Cardiol. 85:2000;36D-45D.
4. Costeas C., Kassotis J., Blitzer M., Reiffel J.A. Rhythm management in atrial fibrillation - with a primary emphasis on pharmacological therapy part 2 . PACE Pacing Clin Electrophysiol. 21:1998;742-752.
5. Kassotis J., Costeas C., Blitzer M., Reiffel J.A. Rhythm management in atrial fibrillation - with a primary emphasis on pharmacological therapy part 3 . PACE Pacing Clin Electrophysiol. 21:1998;1133-1145.
6. Reiffel J.A. Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. Am J Cardiol. 82:(suppl):1998;72N-81N.
7. Cannom D.S. Atrial fibrillation nonpharmacologic approaches: an evolving era . Am J Cardiol. 85:2000;25D-35D.
8. Ellenbogen K.A., Stambler B.S., Wood M.A., Sager P.T., Wesley R.C. Jr, Meissner M.D., Zoble R.G., Wakefield L.K., Perry K.T., VanderLugt J.T. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter a dose-response study . J Am Coll Cardiol. 28:1996;130-136.
9. Stambler B.S., Wood M.A., Ellenbogen K.A., Perry K.T., Wakefield L.K., VanderLugt J.T. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 94:1996;1613-1621.
10. Vos M.A., Golitsyn S.R., Stangl K., Ruda M.Y., Van Wijk L., Harry J.D., Perry K.T., Touboul P., Steinbeck G., Wellens H.J. Superiority of ibutilide (a new class III agent) over d,l-sotalol in converting atrial flutter and atrial fibrillation. Heart. 79:1998;568-575.
11. Volgman A.S., Carberry P.A., Stambler B., Lewis W.R., Dunn G.H., Perry K.T., VanderLugt J.T., Kowey P.R. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 31:1998;1414-1419.
12. Reiffel J.A. Intravenous amiodarone in the management of atrial fibrillation. Pharmacol Ther. 4:1999;199-204.
13. Lehman R, Greenbaum RA, Campbell TJ, Channer KS, Dalrymple HW, Kingma JH, Santini M, Theisen K, Toivonen LK, for the EMERALD Study Group. Patients with longer QT (QTc) interval are more likely to remain in sinus rhythm after one year treatment on dofetilide: the EMERALD study. J Am Coll Cardiol 1999;(suppl):132A. Abstract.
14. Capucci A., Lenzi T., Boriani G., Trisolino G., Binetti N., Cavazza M., Fontana G., Magnani B. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol. 70:1992;69-72.
15. Capucci A., Boriani G., Botto G.L., Lenzi T., Rubino I., Falcone C., Trisolino G., Della Casa S., Binetti N., Cavazza M., Sanguinetti M., Magnani B. Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol. 74:1994;503-505.
16. Capucci A., Villani G.Q., Piepoli M.F., Aschieri D. The role of oral IC antiarrhythmic drugs in terminating atrial fibrillation. Curr Opin Cardiol. 14:1999;4-8.
17. Capucci A., Villani G.Q., Aschieri D., Piepoli M. Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm a prospective parallel placebo-controlled multicentre study . Int J Cardiol. 68:1999;187-196.
18. Oral H., Souza J.J., Michaud G.F., Knight B.P., Goyal R., Strickberger S.A., Morady F. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med. 340:1999;1849-1854.
19. Lau C.-P., Lok N.-S. A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold. PACE Pacing Clin Electrophysiol. 20:1997;2442-2452.
20. Wang M., Dorian P. DL and D Sotalol decrease defibrillation energy requirements. PACE Pacing Clin Electrophysiol. 12:1989;1522-1529.
21. Kowey PR, Reiffel JA. Pharmacokinetics, Antiarrhythmic Drugs, Proarrhythmia. Bethesda, MD: American College of Cardiology/North American Society of Electrophysiology; 1996. Electrophysiology Self-Assessment Program (EPSAP) series, No. 5.
22. Prystowsky E.N. Perspectives and controversies in atrial fibrillation. Am J Cardiol. 82:1998;31-61.
23. Waldo A.L., Prystowsky E.N. Drug treatment of atrial fibrillation in the managed care era. Am J Cardiol. 81:(suppl):1998;23C-29C.
24. Levy S., Breithardt G., Campbell R.W., Camm A.J., Daubert J.C., Allessie M., Aliot E., Capucci A., Cosio F., Crijns H., et al. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J. 19:1998;1294-1320.
25. Reiffel J.A., Camm A.J., Haffajee C.I., et al. International Consensus Roundtable on Atrial Fibrillation. Cardiol Rev. 17:(suppl Feb):2000;1-19.
26. Reiffel J.A., Correia J. "In the absence of structural heart disease. ..." What is it and why does it matter in antiarrhythmic drug therapy? Am Heart J. 128:1994;626-629.
27. Reiffel J.A. Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter. Am Heart J. 135:1998;551-556.
28. Preliminary report effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction (Special Report) . N Engl J Med. 321:1989;406-412.
29. Teo K.K., Yusuf S., Furberg C.D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction an overview of results from randomized controlled trials . JAMA. 270:1993;1589-1595.
30. Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;1142-1147.
31. Torp-Pedersen C., Møller M., Bloch-Thomsen P.E., Køber L., Sandøe E., Egstrup K., Agner E., Carlsen J., Videback J., Marchant B., Camm J. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 341:1999;857-865.
32. Julian D.G., Camm A.J., Frangin G., Janse M.J., Munoz A., Schwartz P.J., Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction EMIAT trial . Lancet. 349:1997;667-674.
33. Cairns J.A., Connolly S.J., Roberts R., Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations CAMIAT . Lancet. 349:1997;675-682.
34. Camm A.J., Karam R., Pratt C.M. The azimilide post-infarct survival evaluation (ALIVE) trial. Am J Cardiol. 81:(suppl):1998;35D-39D.
35. Kowey P.R., Bharucha D.B. Management and prevention of atrial fibrillation after cardiovascular surgery. Am J Cardiol. 85:2000;20D-24D.
36. Daoud E.G., Strickberger S.A., Man K.C., Goyal R., Deeb G.M., Bolling S.F., Pagan F.D., Bitar C., Meissner M.D., Morady F. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med. 337:1997;1785-1791.
37. Guarnieri T., Nolan S., Gottlieb S.O., Dudek A., Lowry D.R. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery the Amiodarone Reduction in Coronary Heart (ARCH) trial . J Am Coll Cardiol. 34:1999;343-347.
38. Reiffel J.A. The ARCH study commentary. Arrhythmia clinic . Cardiol Rev. 17:2000;45.
39. Kowey P.R., Taylor J.E., Rials S.J., Marinchak R.A. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary artery bypass grafting. Am J Cardiol. 69:1992;963-965.
40. Nyström U., Edvardsson N., Berggren H., Pizzarelli G.-P., Rådegran K. Oral sotalol reduces the incidence of atrial fibrillation after coronary artery bypass surgery. J Thorac Cardiovasc Surg. 41:1993;34-37.
41. Janssen J., Loomans L., Harink J., Taams M., Brunninkhuis L., van der Starre P., Kootstra G. Prevention and treatment of supraventricular tachycardia shortly after coronary artery bypass grafting a randomized open trial . Angiology. 37:1986;601-609.
42. Suttorp M.J., Kingma J.H., Peels H.O., Koomen E.M., Tijssen J.G., van Hemel N.M., Defauw J.A., Ernst S.M. Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol. 68:1991;1163-1169.
43. Weber U.K., Osswald S., Baser P., Huber M., Skarvan K., Stulz P., Pfisterer M. Significance of supraventricular tachyarrhythmias after coronary artery bypass graft surgery and their prevention by low-dose sotalol a prospective double-blind randomized placebo-controlled study . J Cardiovasc Pharmacol Ther. 3:1998;209-216.
44. Ip J., Grimes D., Etikerentse T., Santoni F., Mehta D., Pe E., Gomes J.A. A prospective randomized placebo-controlled double-blinded trial of sotalol for the prevention of atrial fibrillation following cardiac surgery. PACE Pacing Clin Electrophysiol. 21:1998;812. Abstract.
45. Parikka H., Toivonen L., Heikkilä L., Virtanen K., Järvinen A. Comparison of sotalol and metoprolol in the prevention of atrial fibrillation after coronary artery bypass surgery. J Cardiovasc Pharmacol. 31:1998;67-73.
46. Suttorp M.J., Kingma J.H., Tjon Joe Gin R.M., van Hemel N.M., Koomen E.M., Defauw J.A.M., Adan A.J.M., Ernst S.M. Efficacy and safety of low- and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations. J Thorac Cardiovasc Surg. 100:1990;921-926.
47. Weber U.K., Osswald S., Huber M., Buser P., Skarvan K., Stulz P., Schmidhauser C., Pfisterer M. Selective versus non-selective antiarrhythmic approach for prevention of atrial fibrillation after coronary surgery Is there a need for pre-operative risk stratification? A prospective placebo-controlled study using low-dose sotalol . Eur Heart J. 19:1998;794-800.
48. Pfisterer M.E., Kloter-Weber U.C., Huber M., Osswald S., Buser P.T., Skarvan K., Stulz P.M. Prevention of supraventricular tachyarrhythmias after open heart operation by low-dose sotalol a prospective, double-blind, randomized, placebo-controlled study . Ann Thorac Surg. 64:1997;1113-1119.
49. Reiffel J.A. Inpatient versus outpatient antiarrhythmic drug initiation safety and cost-effectiveness issues . Curr Opin Cardiol. 15:2000;7-11.
50. Efficacy, safety, and dose-response study of dl-sotalol (Betapace) for prevention of recurrence of atrial fibrillation/atrial flutter (AFIB/AFL). PACE Pacing Clin Electrophysiol. 21:1998;812. Abstract.
51. Pritchett E, Page R, Connolly S, Marcello S, Schnell D, Wilkinson W, ASAP Investigators. Azimilide treatment of atrial fibrillation. Circulation 1998;98:I-663. Abstract.
52. Prystowsky EN. Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia. Clin Cardiol 1994;17:II-7-II-10.
53. Hughes M.M., Trohman R.G., Simmons T.W., Castle L.W., Wilkoff B.L., Morant V.A., Maloney J.D. Flecainide therapy in patients treated for supraventricular tachycardia with near normal left ventricular function. Am Heart J. 123:1992;408-412.
54. Marcus F.I. Risks of initiating therapy with sotalol for treatment of atrial fibrillation. J Am Coll Cardiol. 32:1998;177-180.
55. Barbey J.T., Sale M.E., Woosley R.L. Safety, pharmacodynamics, and pharmacokinetics of an accelerated sotalol dose titration regimen in healthy volunteers. J Am Coll Cardiol. 33:1999;270A. Abstract.
56. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol. 72:1993;280-287.
57. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 337:1997;1576-1583.
58. Reiffel JA, Kowey PR. Generic antiarrhythmics - are they therapeutically equivalent in the therapy of tachyarrhythmias? The experience of practicing electrophysiologists. Am J Cardiol 2000;85.
59. Anonymous. Generic drugs. Med Lett. 41:1999;47-48.
60. Grubb B.P. Recurrence of ventricular tachycardia after conversion from proprietary to generic procainamide. Am J Cardiol. 63:1989;1532-1533.
61. Richton-Hewett S., Foster E., Apstein C.S. Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital. Arch Intern Med. 148:1988;806-808.
62. Sabatini S., Ferguson R.M., Helderman J.H., Hull A.R., Kirkpatrick B.S., Barr W.H. Drug substitution in transplantation a National Kidney Foundation white paper . Am J Kidney Dis. 33:1999;389-397.